Diabetes: A Cinderella Subject We Can’t Afford to Ignore

1. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium International Diabetes Federation. 2015.

2. Xu Y, Wang L, He J, Bi Y, Li M, et al. Prevalence and Control of Diabetes in Chinese Adults. JAMA. 2013; 310: 948–959. doi: 10.1001/jama.2013.168118 24002281

3. InterAct Consortium, Langenberg C, Sharp SJ, Schulze MB, Rolandsson O, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. PLoS Med. 2012; 9: e1001230. doi: 10.1371/journal.pmed.1001230 22679397

4. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829–841. doi: 10.1056/NEJMoa1008862 21366474

5. Ma RC, Chan JC. Diabetes: incidence of childhood type 1 diabetes: a worrying trend. Nat Rev Endocrinol. 2009; 5: 529–530. doi: 10.1038/nrendo.2009.180 19763122

6. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016; 4: 275–285. doi: 10.1016/S2213-8587(15)00521-5 26857998

7. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301: 2129–2140. doi: 10.1001/jama.2009.726 19470990

8. Luk AO, Lau ES, So WY, Ma RC, Kong AP, et al. Prospective study on the incidences of cardiovascular-renal complications in Chinese patients with young-onset type 1 and type 2 diabetes. Diabetes Care. 2014; 37: 149–157. doi: 10.2337/dc13-1336 24356598

9. Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med. 2014; 371: 286–287. doi: 10.1056/NEJMc1406009 25014698

10. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010; 363: 2339–2350. doi: 10.1056/NEJMra0906948 21142536

11. Li G, Zhang P, Wang J, An Y, Gong Q, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014; 2: 474–480. doi: 10.1016/S2213-8587(14)70057-9 24731674

12. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371: 1753–1760. doi: 10.1016/S0140-6736(08)60762-X 18502299

13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577–1589. doi: 10.1056/NEJMoa0806470 18784090

14. Marshall SM. Intensive diabetes management for high-risk patients: how best to deliver? Diabetes Care. 2009; 32: 1132–1133. doi: 10.2337/dc09-0540 19460918

15. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia. 2009; 52: 1219–1226. doi: 10.1007/s00125-009-1352-5 19373446

16. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379: 2252–2261. doi: 10.1016/S0140-6736(12)60480-2 22683130

17. Engelgau MM, Narayan KM, Saaddine JB, Vinicor F. Addressing the burden of diabetes in the 21st century: better care and primary prevention. J Am Soc Nephrol. 2003; 14: S88–91. 12819309

18. C3 Collaborating for Health. Urban Health Promotion: Selected Case Studies on Diabetes. 2015; www.c3health.org.